OHRP News Alert Ohr Pharmaceutical Inc (OHRP) 7.38 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 11:10 PM

Ohr Pharmaceutical Inc (OHRP) 7.38 $OHRP

Ohr Pharmaceutical concludes public offering at USD6.75 per share
M2 - Thu Feb 12, 5:16AM CST
Ophthalmology company Ohr Pharmaceutical (NasdaqCM:OHRP) revealed on Wednesday the completion of its public offering of common stock at USD6.75 per share.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock
GlobeNewswire - Wed Feb 11, 11:54AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it has closed its previously announced public offering of common stock. The Company sold 4,259,259 common shares in the offering, including 555,555 shares that were issued upon the full exercise by the underwriters of their over-allotment option. The offering price was $6.75 per share, and the gross proceeds to the Company from the sale of the shares were approximately $28.8 million. The transaction was led by new investors Deerfield Management Company, L.P., and Broadfin Capital LLC, and included participation from new and existing investors.
OHRP: 7.38 (-0.30)

OHR reports 1Q loss
Automated Insights - Mon Feb 09, 4:16PM CST
SALT LAKE CITY, Utah (AP) _ Ohr Pharmaceutical Inc. (OHRP) on Monday reported a loss of $4.6 million in its fiscal first quarter.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical beats by $0.02
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:56PM CST

OHRP: 7.38 (-0.30)

Ohr Pharmaceutical Reports Fiscal First Quarter 2015 Financial and Business Results
GlobeNewswire - Mon Feb 09, 3:01PM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its first fiscal quarter ended December 31, 2014.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical (OHRP) in Focus: Stock Falls 8.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 7:30AM CST
Ohr Pharmaceutical saw a big move last session, as the company’s shares fell by over 8% on the day.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York
GlobeNewswire - Mon Feb 09, 7:06AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive Officer, will present a corporate overview and business update at the 17 Annual BIO CEO & Investor Conference, and the Leerink Global Healthcare Conference.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical prices public offering at USD6.75 per share
M2 - Mon Feb 09, 6:09AM CST
Ophthalmology company Ohr Pharmaceutical (NasdaqCM:OHRP) stated on Friday that it has priced a public offering of 3,703,704m shares of its common stock.
OHRP: 7.38 (-0.30)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 8:12AM CST

HRS: 77.73 (+0.42), GPRO: 45.27 (-0.02), NLST: 1.86 (unch), TROV: 4.99 (-0.17), AU: 12.33 (+0.36), NMM: 12.37 (+0.24), EOX: 1.15 (unch), NBG: 1.61 (+0.18), ONTY: 1.57 (unch), ATVI: 23.11 (+0.17), PBR: 6.98 (+0.44), XLS: 24.15 (+0.04), MHR: 2.62 (+0.11), CIG: 4.29 (+0.10), PWE: 2.45 (+0.02), LNKD: 269.00 (+1.83), GDP: 3.58 (+0.29), SFY: 2.91 (+0.26), P: 15.44 (+0.45), TPX: 55.62 (+1.71), EXPE: 89.49 (-0.08), OHRP: 7.38 (-0.30), TWTR: 48.50 (+0.55), YELP: 47.53 (-0.10)

Ohr Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 7:46AM CST

OHRP: 7.38 (-0.30)

Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock
GlobeNewswire - Fri Feb 06, 7:30AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced the pricing of its previously announced underwritten public offering of 3,703,704 million shares of its common stock at a public offering price of $6.75 per share for gross proceeds of approximately $25 million, before deducting estimated underwriting discounts and commissions and other estimated offering expenses. Ohr has also granted the underwriters a 30-day option to purchase up to an additional 555,555 shares of common stock from Ohr to cover overallotments, if any, which would result in additional gross proceeds of approximately $3.8 million if exercised in full. Ohr intends to use the net proceeds from the public offering to fund clinical trials of OHR-102, the development of its preclinical pipeline, and other general corporate purposes. The offering is expected to close on February 11, 2015, subject to customary closing conditions.
OHRP: 7.38 (-0.30)

Ohr Pharma plans equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 3:19PM CST

OHRP: 7.38 (-0.30)

Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Feb 05, 3:10PM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an underwritten public offering. Ohr Pharmaceutical also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering to cover overallotments, if any. Ohr Pharmaceutical plans to use the net proceeds from the offering to fund clinical trials of OHR-102, the development of its pre-clinical pipeline and for general corporate purposes.
OHRP: 7.38 (-0.30)

Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
ITEK: (), NBS: 3.78 (+0.14), FOMX: 9.01 (-0.03), AERI: 27.91 (+0.14), OCUL: 31.25 (-0.01), AGN: 229.49 (+1.87), CANF: 3.85 (+0.05), ACAD: 34.21 (+0.37), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), OHRP: 7.38 (-0.30), CBMG: 24.32 (-1.17)

Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, to Board of Directors
GlobeNewswire - Thu Jan 08, 7:49AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has been appointed to the Company's Board of Directors.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical posts higher net loss of USD9.1m for fiscal 2014
M2 - Wed Dec 24, 3:40AM CST
Ophthalmology company Ohr Pharmaceutical (NasdaqCM:OHRP) reported on Tuesday its net loss of USD9.1m (USD0.41 per share) for its fiscal year ended 30 September 2014.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical's (OHRP) CEO Irach Taraporewala on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Dec 22, 9:59PM CST

OHRP: 7.38 (-0.30)

Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results
GlobeNewswire - Mon Dec 22, 3:10PM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its fiscal year ended September 30, 2014.
OHRP: 7.38 (-0.30)

Ohr Pharmaceutical to Announce Fiscal 2014 Financial Results and Host Conference Call on Monday, December 22
GlobeNewswire - Fri Dec 19, 7:00AM CST
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will report its financial results for the 2014 fiscal year ended September 30, 2014 after the close of the market and host a corporate update conference call and webcast on Monday, December 22, 2014 at 5:00pm Eastern Time.
OHRP: 7.38 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FLUX 3 Max Launches with Unmatched Speed and Quality

A Lightning Fast Leap in Video Generation It's all eyes on FLUX 3 Max today. You can almost hear the gasps of 'wow' in the generative media crowd. Why? Because this new weapon in the video gen arsenal, dreamed up by fal and Black Forest Labs, is slicing through the old speed limits like a blistering comet. Now, don't get me wrong. Seeds don't grow overnight, and neither...

D2L Ventures into Vietnam with Van Lang Alliance

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Navigating the Nitty-Gritty of Cabin Rental Management

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

CourseArc Partners with Colleges for ADA Compliance

CourseArc's Landmark Deal with Public Colleges Well, slap me silly and call me a believer—looks like CourseArc just locked down a heck of a gig with a public college system that's head-over-heels squirming to meet shiny new accessibility demands. Nearly 200,000 learners are waiting at their gates, and this agreement is the lifeline for colleges to not only stay afloat...

Minnesota Cremation Services Expands Reach Statewide

Compassionate Expansion Reflecting Community Needs You talk to just about any family facing the heart-wrenching task of making decisions for a loved one's final farewell, and the story ain't pretty. Pricey packages, pressure to upgrade, and a constant side-eye wondering if they're getting the real deal. For Minnesota Cremation Services, though, this expansion is about...

University of Phoenix Lowers Costs for Transfer Students

The Pocket-Saving Game of Transfer Credits Here's the buzz: the University of Phoenix is putting some serious coin back into students' pockets through transfer credits. We're looking at more than $12,010 in savings per student, thanks to these policies, which is no chump change by any stretch. As over 900,000 credits were tossed into the pot, the savings side of education...

PrePass Intelligence: A Game-Changer for Fleets

Picture this: you're at the wheel of a beastly 18-wheeler, barreling down the highway and skipping weigh stations thanks to PrePass. But here’s where the real magic kicks in. PrePass Intelligence just rolled out, aiming to squeeze every last drop of value from bypass and toll data. That's cold hard cash for fleet operators who can finally make sense of these fleeting...

Bryan Cranston Stars in Live Streaming 'A Christmas Carol'

Cranston Climbs Into Scrooge's Shoes for a Cause If you think you've got the holiday season all figured out, add this curveball: Bryan Cranston as Ebenezer Scrooge, jawing through "A Christmas Carol" as part of a unique, one-night-only staged reading. And it's not just another star-studded ploy for attention. It's about rallying around a cause bigger than holiday cheer,...

Millrose Investors Face Unveiling of Financial Missteps

A Cold Shower for Millrose Properties' Investors Investing in Millrose Properties, Inc. (NYSE: MRP) didn't quite pan out as some folks hoped. On the heels of Hunterbrook's report about dubious deals, the Company's stock tumbled 8.53%, smacking investors with a not-so-gentle reminder of market realities. Sure, stocks can dip and dive like a rollercoaster, but when it...

PG&E Delivers $26M Climate Credit to Small Biz

California's Big Move for Small Businesses In a world where every dollar counts, small businesses across Northern and Central California are getting a helping hand. Pacific Gas and Electric Company (PG&E) is stepping up with a tidy little climate credit thanks to the state's Cap-and-Invest Program. Eligible businesses are automatically set to receive a $36.18 credit off...